期刊
SUPPORTIVE CARE IN CANCER
卷 26, 期 -, 页码 S5-S9出版社
SPRINGER
DOI: 10.1007/s00520-018-4131-3
关键词
Chemotherapy-induced nausea and vomiting; CINV; NK-1 receptor antagonist; 5-HT3 receptor antagonist; Anticipatory CINV; Breakthrough CINV
资金
- Merck and Co, Inc.
- TESARO, Inc.
Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared side effects experienced by patients with cancer. The precise physiologic mechanisms responsible for acute and delayed CINV continue to be elucidated and have provided an opportunity to develop antiemetic therapies targeting these pathways. The emergence of receptor antagonists targeting serotonin and neurokinin-1 have revolutionized the prevention of CINV, significantly reducing the impact of this side effect and improving patient quality of life. However, several areas of unmet need remain, including adequate prevention of nausea, rather than just vomiting, in patients receiving chemotherapy for cancer. Prevention of delayed CINV and anticipatory CINV, as well as management of breakthrough CINV, also continues to challenge patients and clinicians. Ongoing research continues to address these areas to improve antiemetic therapies and guidelines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据